With URL, Takeda Looks To Become U.S. Gout Therapy Provider Of Choice
This article was originally published in PharmAsia News
Executive Summary
In purchasing privately held URL for $800 million, Takeda acquires gout drug Colcrys, which it will market alongside Uloric.
You may also be interested in...
Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication
FDA’s Arthritis Advisory Committee will consider the interleukin-1 blocker for prevention of gout flares during initiation of uric-acid lowering therapy. Analysts say Arcalyst could have an easier time than Novartis’ Ilaris, which the panel felt had serious infection safety issues.
Colcrys Promo Eats Pavement As FDA Objects To Ad Of Motorcyclist Holding Teacup
FDA asks Mutual to stop using a pharmacy sell sheet that describes the gout drug as “gentle.” It also cites a video for failing to convey serious risk information and suggesting the drug is as tolerable as a placebo and superior to NSAIDs.
Novartis' Ilaris For Gout: FDA Questions Whether Symptom Relief Is Worth Risks
The agency will also ask its Arthritis Advisory Committee at a June 21 meeting whether the sponsor should explore lower doses for the interleukin-1 beta inhibitor.